I agree. Many investors, myself included, hoped the scores would have been higher, maybe twice or three times the difference from placebo. If that had been the case we would likely be looking at mega funding from others and a much faster track to approval. Results do however show more than a simple trend line move in the right direction IMO. A score difference of 4, 5 weeks in, was easily stat sig. The problem at week 9 was that the placebo score increased a full point unexpectedly before falling off again but was still higher in week 13 than week 5 on the SIB scale. That made for a really tough result as far as stat sig is concerned. IF the 30 day 17 week follow up sustained improvement and the placebo returned to a traditional pattern we would once again be stat sig. Not trying to be too technical but just explaining why its easy for some to dismiss the study due to a single data point without reading the entire study. This is why a placebo controlled study is so important. We know what we have and don't have to guess at it.
That said, there are going to be no quick approvals here. Milestones such as FragileX, or extensions, or partnerships, or oral versions of the drug, etc will come along. The science excites me so I'll be following. We don't have immediate need for funding this year but at some point we will and who knows when that will be or what form it takes. Stocks don't trade well with uncertainty and as positive as some of us think the data is, its hard to say where the stock goes until further clarity. What we do know is it can move fast and hard with good news. All depends on an investor's time frame. JMHO
News 
Market Data 
Discover 
